These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Preparing for the introduction of new technologies: who is going to pay for them? Marshall PR J Cardiovasc Manag; 2002; 13(1):14-20. PubMed ID: 11828780 [No Abstract] [Full Text] [Related]
23. [Drug-eluting coronary stents]. Fontos G Orv Hetil; 2006 Oct; 147(43):2059-66. PubMed ID: 17297752 [TBL] [Abstract][Full Text] [Related]
25. A stent is not just a stent: Stent construction and design do matter in its clinical performance. Lau KW; Johan A; Sigwart U; Hung JS Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045 [TBL] [Abstract][Full Text] [Related]
26. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Beijk MA; Piek JJ Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467 [TBL] [Abstract][Full Text] [Related]
27. Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents. Halpern MT; Lacey M; Clark MA; Valentin MA BMC Cardiovasc Disord; 2004 Dec; 4():23. PubMed ID: 15596004 [TBL] [Abstract][Full Text] [Related]
28. Learning new lines. New 'playbook' advises hospitals how to win bigger reimbursement for medical procedures that use expensive advanced technology. Taylor M Mod Healthc; 2003 Jul; 33(30):6-7, 1. PubMed ID: 12929254 [TBL] [Abstract][Full Text] [Related]
29. [Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents]. Gulizia M; Martelli E; Tamburino C; Tolaro S; Frasheri A; Giambanco F; Grassi R; Fiscella A; Milazzo D Ital Heart J Suppl; 2004 Aug; 5(8):630-8. PubMed ID: 15554018 [TBL] [Abstract][Full Text] [Related]
30. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions. Ray GM; Nawarskas JJ; Frishman WH Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023 [TBL] [Abstract][Full Text] [Related]
31. Assessing the impact of drug-eluting stents. Hospitals must be prepared to absorb a potentially negative financial impact. Pfeiffer H Healthc Exec; 2003; 18(4):60-1. PubMed ID: 12841062 [No Abstract] [Full Text] [Related]
32. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of drug-eluting stents in coronary angioplasty. Santos R; Pereira H Rev Port Cardiol; 2005 Nov; 24(11):1409-18. PubMed ID: 16463989 [TBL] [Abstract][Full Text] [Related]
34. A one-year comparison of cost and outcomes of angioplasty in stent and nonstent patients. Sen SS; Khandker RK; Roth DA; Thomas J Am J Ther; 2005; 12(3):210-7. PubMed ID: 15891263 [TBL] [Abstract][Full Text] [Related]